摘要
目的探讨阿司匹林和尼莫地平用于治疗偏头痛的临床效果及安全性。方法选取2018年1月~2019年6月某院收治的100例偏头痛患者作为研究对象,采用随机数字表法分为对照组与观察组,每组各50例。对照组患者采用尼莫地平治疗,观察组患者采取阿司匹林治疗。比较两组患者的治疗总有效率、不良反应、偏头痛发作情况以及复发率。结果观察组患者的治疗总有效率为92.00%,高于对照组的72.00%,差异有统计学意义(P<0.05)。观察组患者的不良反应总发生率为8.00%,低于对照组的28.00%,差异有统计学意义(P<0.05)。治疗后观察组患者的偏头痛发作次数少于对照组,持续时间短于对照组,视觉模拟量表(VAS)评分低于对照组,差异均有统计学意义(P<0.05)。观察组患者的复发率为4.00%,低于对照组的20.00%,差异有统计学意义(P<0.05)。结论针对偏头痛患者,采取阿司匹林治疗相较于尼莫地平,效果显著,适宜临床应用推广。
Objective To investigate the effect and safety of Aspirin and Nimodipine in the treatment of migraine.Methods A total of 100 patients with migraine admitted to the hospital from January 2018 to June 2019 were selected as the research objects and divided into the control group and the observation group by random number table method,with 50 patients in each group.The control group was treated with Nimodipine,while the observation group was treated with Aspirin.The total effective rate,adverse reactions,migraine attacks and recurrence rates of the two groups were compared.Results The total effective rate of the observation group(92.00%)was higher that of the control group(72.00%),and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group(8.00%)was lower than that in the control group(28.00%),and the difference was statistically significant(P<0.05).After treatment,the number of migraine attacks in the observation group was less than that in the control group,duration of migraine in the observation group was shorter than that in the control group,the visual analogue scale(VAS)score of the observation group was lower than that of the control group,and the differences were statistically significant(P<0.05).The recurrence rate of the observation group(4.00%)was lower than that of the control group(20.00%),and the difference was statistically significant(P<0.05).Conclusion For patients with migraine,Aspirin treatment is more effective than Nimodipine,which is suitable for clinical application and promotion.
作者
孙辉
罗世书
王玉娟
SUN Hui;LUO Shi-shu;WANG Yu-juan(Shaanxi Institute of Food and Drug Supervision and Inspection,Shaanxi Province,Xi′an710065,China;Department of Pharmacy,the 960th Hospital in Ji′nan City,Shandong Province,Ji′nan250031,China)
出处
《中国当代医药》
2020年第36期148-150,共3页
China Modern Medicine
